+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 30Years - 75Years
All Genders
ID03308916

Screening for Advanced Liver Fibrosis Using Non-invasive Tests in Adults at Risk and General Population

Led by Maja Thiele · Updated on 2022-09-01

6500

Participants Needed

1

Research Sites

513 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the use of transient elastography and other blood and imaging tests to detect advanced liver fibrosis in people at risk for liver diseases such as non-alcoholic fatty liver disease and alcoholic fatty liver disease. This prospective screening study at Odense University Hospital aims to assess how well transient elastography works as a screening tool by measuring its benefits, harms, detection rates, technical use, and ability to predict outcomes. The study includes a control group from the general population to compare findings. Participants include 3000 people at risk due to long-term alcohol overuse or metabolic syndrome with or without type 2 diabetes, along with 3500 from the general population. Everyone undergoes liver stiffness measurement using transient elastography while fasting. Those with elevated liver stiffness above 8.0 kiloPascal will have further tests including shear-wave elastography, abdominal ultrasound, and possibly a liver biopsy to confirm advanced fibrosis. After one year, participants with positive or at-risk results will have repeat tests, and those with increasing stiffness may be offered a second biopsy no sooner than two years after the first. During the study, participants will have liver stiffness measurements, blood tests for various fibrosis markers, and imaging studies. All participants will be followed for 10 years to monitor liver-related health outcomes and overall survival. The main outcomes measured are biopsy-confirmed advanced fibrosis at 5 years and liver-related events over 10 years, providing long-term insight into liver disease progression and the value of non-invasive screening methods.

CONDITIONS

Brief Title

Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers

Research Team

M

Maja Thiele, MD, PhD, Professor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here